Latest news with #ElianaMerle
Business Insider
4 days ago
- Business
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
analyst Alex Thompson CFA maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) yesterday and set a price target of $68.00. The company's shares closed yesterday at $47.66. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Oruka Therapeutics, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -2.8% and a 45.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on June 3. However, on May 30, Bank of America Securities maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). The company has a one-year high of $53.27 and a one-year low of $19.45. Currently, Kymera Therapeutics has an average volume of 856.8K.
Business Insider
26-05-2025
- Business
- Business Insider
Kymera Therapeutics (KYMR) Initiated with a Buy at Stifel Nicolaus
In a report released today, Alex Thompson CFA from Stifel Nicolaus initiated coverage with a Buy rating on Kymera Therapeutics (KYMR – Research Report) and a price target of $55.00. The company's shares closed last Friday at $29.49. Confident Investing Starts Here: Thompson CFA covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Argenx Se, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -5.8% and a 40.68% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on May 13. However, on May 12, Bank of America Securities reiterated a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). Based on Kymera Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.1 million and a GAAP net loss of $65.58 million. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $48.56 million Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year. Most recently, in March 2025, Jeremy Chadwick, the COO of KYMR sold 1,383.00 shares for a total of $42,103.92.
Yahoo
24-04-2025
- Business
- Yahoo
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes. That rise was slightly more pronounced than the S&P 500 index's 2.5% increase. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » According to reports, Merle's update was based on surveys with medical professionals indicating that the company's next-generation Journavx pain relief treatment is seeing a notable increase in demand. The second of the pair was part of a broader dive into the current state of pharmaceutical stocks by investment bank Cantor Fitzgerald. The firm presented its new rankings for some of the top names in the field, and flagged Vertex as an overweight (i.e., buy) at $535 per share. With that tag, Vertex joined sector luminaries such as Zepbound developer Eli Lilly and AbbVie as being buy candidates, in the researcher's view. Cantor Fitzgerald was more bearish on others, like Pfizer and Amgen, which it rated only neutral. Vertex is appealing simply by virtue of its business strategy; it concentrates on afflictions with high unmet needs. It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates. I think this stock is well worth a look as a somewhat offbeat way to play the biotech and pharma spaces. Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $532,771!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $593,970!* Now, it's worth noting Stock Advisor's total average return is 781% — a market-crushing outperformance compared to 149% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, Pfizer, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday was originally published by The Motley Fool Sign in to access your portfolio
